Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients

Current factor IX (FIX) products display a half-life (t(1/2)) of ∼ 18 hours, requiring frequent intravenous infusions for prophylaxis and treatment in patients with hemophilia B. This open-label, dose-escalation trial in previously treated adult subjects with hemophilia B examined the safety and pha...

Full description

Saved in:
Bibliographic Details
Main Authors: Shapiro, Amy D., Ragni, Margaret V., Valentino, Leonard A., Key, Nigel S., Josephson, Neil C., Powell, Jerry S., Cheng, Gregory, Thompson, Arthur R., Goyal, Jaya, Tubridy, Karen L., Peters, Robert T., Dumont, Jennifer A., Euwart, Donald, Li, Lian, Hallén, Bengt, Gozzi, Peter, Bitonti, Alan J., Jiang, Haiyan, Luk, Alvin, Pierce, Glenn F.
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2012
Subjects:
Clinical Trials and Observations
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3265197/
https://ncbi.nlm.nih.gov/pubmed/22110246
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-07-367003
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items